The Alzheimer's Association announced the $100 million PROTECT-Cog Study on July 13, 2026, at the Alzheimer's Association International Conference in London, according to the Association announcement. PROTECT-Cog stands for Prevention of Risk fOr cogniTive dEcline through Combined Therapy and tests a proven multidomain lifestyle program plus a metabolism-targeting drug such as a GLP-1 agonist.
For adults with memory concerns, the practical question is fit. This is a prevention trial for at-risk adults without diagnosed disease, not a treatment for people who already have Alzheimer's or dementia. That distinction shapes who should call, what to ask, and what to expect.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is this trial for?
- What would participation involve?
- What are the limits to understand first?
- What should you ask before volunteering?
Who is this trial for?
PROTECT-Cog will enroll older adults at increased risk for decline, according to the study launch summary. Risk here means factors that raise the chance of future decline, not a diagnosis of mild cognitive impairment or dementia. Adults who already have Alzheimer's or dementia fall outside this prevention design.
The approach builds on U.S. POINTER, a two-year, five-site trial of 2,111 cognitively unimpaired at-risk adults. That study combined structured diet, exercise, cognitive training, and health monitoring and improved global cognition. PROTECT-Cog extends that lifestyle model and adds a drug question.
What would participation involve?
The three-year global trial compares intensive coaching with a structured-lite version of the same lifestyle content. Both groups receive the same core topics in diet, activity, brain training, and health tracking. Evaluations occur every six months.
A subset will also add a metabolism or immune-modulating drug. Researchers will track onset of mild cognitive impairment, frailty, quality of life, and general health, according to NeurologyLive's report. Expect repeated visits, lifestyle logs, cognitive tests, and health checks over the full period.
What are the limits to understand first?
GLP-1 drugs remain unproven for dementia prevention. Oral semaglutide in the EVOKE and EVOKE+ trials, with 3,808 participants, lowered inflammation but did not slow decline on CDR-SB. That result matters because inflammation improvement alone did not preserve thinking or daily function.
Lifestyle programs also demand time and follow-through. Coaching, exercise sessions, diet changes, and computer-based brain training compete with work, caregiving, and health issues. Benefits seen in a controlled trial may feel smaller in daily life.
What should you ask before volunteering?
Use Alzheimer's Association TrialMatch at 800-272-3900 to find studies and confirm current openings. Have recent visit notes, medication lists, and family history ready. Ask how your regular doctor stays informed during the trial.
- What are the drug risks, side effects, and monitoring plan for my age and health?
- How long is participation, how often are visits, and are remote options allowed?
- What costs, travel, parking, or caregiver time will I pay?
- How do you share test results with me and my doctor?
- What happens if my memory worsens or I want to leave?
